

# The Neuro4D Conference 2023

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE  
DISEASE  
DRUG  
DISCOVERY

**MONDAY  
MAY 15<sup>TH</sup>**

<b>7:30</b>		
Registration and Joint Breakfast (Please attach posters!)		
<b>8:30</b>		
Opening of the Conference by Andreas Köpke – bioExert		
<b>9:00</b>		
<b>Alzheimer's Disease Progression and Treatment Options</b>	Cellular Dysfunction and Tau Pathology in Alzheimer's diseases: Mechanisms and Drug Development	<b>Rakez Kayed</b> University of Texas Medical Branch, USA
<b>PANEL 09:30 – 10:30</b>		
<b>AD Disease Mechanism</b>	Reverting pathological post-translational protein modification in AD and PD	<b>Steffen Rossner</b> Uni Leipzig, Germany
	Small Molecule Inhibitors of Histone Acetyltransferases CBP and P300 for treatment of Alzheimer's Disease	<b>Ottavio Arancio</b> Taub Institute NYC, USA
<b>Enabling Technology</b>	Novel tools for drug discovery in neurodegenerative diseases	<b>Jacob McPhail</b> Stressmarq, Canada
<b>Panel Q&amp;A of Session Speakers</b> <i>Chair: Rakez Kayed, University of Texas Medical Branch, USA</i>		
<b>10:30 – 11:30</b>		
<b>Coffee Break, Exhibition &amp; Poster Session</b> (All presenters are at their poster for discussion.)		
<b>PANEL 11:30 – 12:30</b>		
<b>AD New Treatment Strategies (preclinical)</b>	A novel druggable target for Alzheimer's disease: the oxidized conformer of macrophage migration inhibitor (MIF)	<b>Andreas Müller-Schiffmann</b> Heinrich Heine University, Germany
<b>Enabling Technology</b>	Effects of partial reduction of amyloid- $\beta$ production on synaptic function <i>in vitro</i>	<b>Lotta Agholme</b> Celletricon, Sweden
<b>New Treatment Strategies (preclinical)</b>	Misfolded DISC1 protein aggregates as a druggable disease mechanism in schizophrenia	<b>Carsten Korth</b> Heinrich Heine University, Germany
<b>Panel Q&amp;A of Session Speakers</b> <i>Chair: Rakez Kayed, University of Texas Medical Branch, USA</i>		
<b>12:30</b>		
Lunch		

# The Neuro4D Conference 2023

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport




DEGENERATIVE  
DISEASE  
DRUG  
DISCOVERY

**MONDAY  
MAY 15<sup>TH</sup>**

<b>13:30</b>		
From Disease Insights to Therapeutic Options	A $\beta$ oligomer targeting in Alzheimer disease	<b>Neil Cashman</b> ProMIS, Canada
<b>PANEL 14:00 – 15:00</b>		
AD Drug Discovery	Amisulpride as a disease-modifying drug for tauopathies	<b>Josephine Labus</b> MHH, Germany
Disease Models	Phenotypic Screening of Novel Compounds for Behavioral Aggression in Alzheimer's Disease	<b>Irene Morganstern</b> PsychoGenics, USA
AD Drug Discovery	Fighting neuroinflammation: THIK-1 as a potential new target	<b>Michael Harte</b> University of Manchester, UK
Panel Q&A of Session Speakers Chair: Neil Cashman, University of British Columbia, Canada		
<b>15:00 – 17:00</b>		
Coffee Break, Exhibition & Poster Session (All presenters are at their poster for discussion. Please vote for the best poster!) One on One Meetings		
<b>PANEL 17:00 – 18:00</b>		
AD Drug Discovery	Disassembly of toxic oligomers by anti-prionic drugs: evidence from animal studies and from patient derived material ex vivo	<b>Antje Willuweit</b> PriAvoid, Germany
Disease Model	Inflammation and AD: Preclinical Drug Testing Systems	<b>Tina Löffler</b> QPS, Austria
AD Drug Discovery	tbd	<b>Achim Schneeberger</b> ADvantage Therapeutics, Austria
Panel Q&A of Session Speakers Chair: Neil Cashman, University of British Columbia, Canada		
<b>18:00</b>		
Local micro brewery beer tasting in the foyer		
<b>19:00 – 22:00</b>		
Dinner We will have a seated barbeque dinner, accompanied by fitting local wines! Depending on the weather, we will be on the hotel terrace, or in an adjacent room.		
<b>END OF THE FIRST DAY</b>		

# The Neuro4D Conference 2023

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



**TUESDAY  
MAY 16<sup>TH</sup>**

<b>7:30</b>		
<b>Joint Breakfast and Poster Session</b> (Please vote for the best poster!)		
<b>8:30</b>		
<b>New late preclinical and early clinical candidates</b>	Late preclinical / early clinical AD targets beyond anti-amyloid approaches	<b>Knut Biber</b> Abbvie, Germany
<b>PANEL 9:00 – 10:00</b>		
<b>AD Models for late preclinical validation</b>	New biomarkers for investigating test items in the aged dog AD model	<b>Joseph Araujo</b> Transpharmation, Canada
<b>Novel AD Treatment Approach</b>	tbd	tbd
	tbd	tbd
<b>Panel Q&amp;A of Session Speakers</b> Chair: Knut Biber, Abbvie, Germany		
<b>10:00 – 11:00</b>		
<b>Coffee Break, Exhibition &amp; Poster Session</b> (All presenters are at their poster for discussion. Final chance to vote for the best poster!) <b>Time for One on One Meetings</b>		
<b>PANEL 11:00 – 12:20</b>		
<b>AD Biomarker</b>	Molecular analysis of nasal secretion to identify early stages of Alzheimer disease	<b>Mareike Haack</b> Noselab, Germany
	Development of MS-based therapy-response biomarkers for Alzheimer's disease	<b>Stefan Lichtenthaler</b> German Center for Neurodegenerative Diseases (DZNE) and TUM
	Utility of four serum biomarkers for the diagnosis of Alzheimer's Disease	<b>Carola Schipke</b> Predemtech AG, Germany
	Oligomers count!	<b>Oliver Bannach</b> Attyloid, Germany
<b>Panel Q&amp;A of Session Speakers</b> Chair: Knut Biber, Abbvie & Oliver Peters, Charité		
<b>12:20</b>		
<b>Lunch</b>		

# The Neuro4D Conference 2023

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



**TUESDAY  
MAY 16<sup>TH</sup>**

13:30		
Clinical Studies in Alzheimer's Diseases	Recent defeat and new hopes!	<b>Oliver Peters</b> Charité, Germany
PANEL 14:00 – 15:00		
AD Clinical Trial	Lessons from Gantenerumab Phase III trials	<b>Martin Traber</b> Roche, Switzerland
	Phase Ib results and phase II design for PRI-002 in MCI and mild Alzheimer's dementia	<b>Dieter Willbold</b> Priavoid, Germany
	Current Directions in the Treatment of Alzheimer's Disease: Results from the Phase III Study CLARITY AD	<b>Lutz Frölich</b> ZI Mannheim, Germany
Pannel Q&A of Session Speakers <i>Chair: Oliver Peters, Charité, Germany</i>		
15:00		
Coffee Break (Please collect your posters!)		
15:30		
Pannel Diskussion: Are the new treatments worth their risks? We will discuss clinical efficacy and the perceived risk-benefit ratio. <i>Moderator: Andreas Köpke, bioExpert</i>		
16:15		
Price for the Best Poster – <i>Scientific Progress towards improving the Life of Patients and their Families – presented at the International Neuro4D Conference 2023</i>		
16:25		
Summary and Wrap-Up of the Conference		
16:30		
END OF THE CONFERENCE AND DEPARTURE		